Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck
Nicole G. Chau(University of British Columbia), Christopher A. French(Harvard University), Carlos Rodríguez‐Galindo(St. Jude Children's Research Hospital), Noam Grunfeld(Brigham and Women's Hospital), Daniel E. Bauer(Broad Institute), Roy B. Tishler(Dana-Farber Cancer Institute), Peter Hsi(Tufts University), Robert I. Haddad(Georgetown University), Stephen E. Sallan, Leah Kaplan(Brigham and Women's Hospital), Chelsey M. Mitchell(Brigham and Women's Hospital), Shelley Hurwitz(Harvard University), James E. Bradner(Novartis (China)), Christopher S. Lathan(Harvard University), Alexandra Aserlind(Brigham and Women's Hospital)
Cited by 210
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
CRISPResso2 provides accurate and rapid genome editing sequence analysis
|Nature Biotechnology|2019|1.8k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k